Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione

A kind of technology of morpholino methyl and indoline, applied in utilizing 3-(4-((4-(morpholinomethyl) benzyl)oxy)-1-oxoisoindoline In the field of cancer treatment with dol-2-yl)piperidine-2,6-dione, it can solve problems such as lack of response to rituximab

Inactive Publication Date: 2015-08-12
CELGENE CORP
View PDF25 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

High J-chain expression in rheumatoid arthritis (RA) patients predicts lack of response to rituximab

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
  • Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
  • Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0115] Provided herein is a method for treating, managing or preventing cancer, comprising treating or preventing an effective amount of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisobis Indolin-2-yl)piperidine-2,6-dione or its enantiomer or mixture of enantiomers or its pharmaceutically acceptable salt, solvate, hydrate, co-crystal, A clathrate or polymorph is administered to a patient in need of such treatment, management or prevention as a single agent or as part of a combination therapy. In some embodiments, the compound is (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl ) piperidine-2,6-dione. In some embodiments, the compound is (R)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl ) piperidine-2,6-dione.

[0116] In certain embodiments, 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1 -Oxoisoindolin-2-yl)piperidine-2,6-dione or its enantiomer or mixture of enantiomers or its pharmaceutically acceptable salt, solvate, hydrate Compounds, co-crystal...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Provided herein are methods of treating, preventing and / or managing cancers, which comprise administering to a patient 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.

Description

[0001] This application claims priority to U.S. Provisional Application No. 61 / 681,447, filed August 9, 2012, and U.S. Provisional Application No. 61 / 722,727, filed November 5, 2012, which are hereby incorporated by reference in their entirety . 1. Technical field [0002] Provided herein are methods of treating, preventing and / or managing cancer comprising administering to a patient 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindoline Indol-2-yl)piperidine-2,6-dione or its enantiomer or mixture of enantiomers or its pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate substances or polymorphs. 2. Background of the invention [0003] 2.1 Cancer Pathology [0004] Cancer is primarily characterized by an increase in the number of abnormal cells originating from a given normal tissue, the invasion of adjacent tissues by these abnormal cells, or the lymphatic or hematogenous spread of malignant cells to local lymph nodes and distant sites (metastases). ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/5377G01N33/50A61P35/00
CPCA61K45/06A61K39/395A61K31/5377A61P35/00A61P35/02A61P43/00A61K31/573A61K9/0053A61K9/48C07D413/14G01N33/50
Inventor 彼得·H·谢弗阿尼塔·甘地
Owner CELGENE CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap